characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2023-03-21T16:00:05Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2023-03-21T16:00:05Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA110169623
characteristics.characteristic: External Id
characteristics.text: Mayo Clinic
characteristics.characteristic: INSDC center name
characteristics.text: 2023-03-21T16:00:05Z
characteristics.characteristic: INSDC first public
characteristics.text: 2023-03-21T16:00:05Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS12268437
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-11740:GPDX 13 Vehicle
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.characteristic: broker name
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: Protocols: Both PDXs are from adults. The tissue is Pancreas and it was the initial tumor site. PDX13 was established from surgically resected tumor tissue from a PDAC patient at the Ruhr-University Bochum Comprehensive Cancer Center. Informed and written consent was obtained. Approval by the ethics committee of the Ruhr University Bochum was obtained under Permission no. 3534-9, 3841-10, 16-5792. Experiments were performed according to the guidelines of the local Animal Use and Care Committees at the Ruhr University Bochum (8.87-50.10.32.09.018, 84-02.04.2012.A328 and 81-02.04.2017.A423). Establishment: Tumor tissues was implanted in NMRInu/nu mice (both flanks). Tumors were expanded and re-implanted for at least three generations. Treatment: 1-2mm of tumor tissue (early passage) were implanted subcutaneously in 5-10-week-old mice (NMRInu/nu). Treatment was started when tumors were approximately 100-200 mm3 in size. Mice were randomized into vehicle (09.% saline) or Gemcitabine/Paclitaxel (100/30 mg/kg).cells were collected and washed in PBS once, while 30mg of PDX were homogenized using Biomasher II (VWR). RNA was extracted using TRIzol 5 prime RBA adaptors were ligated using T4 RNA ligase. Phusion High Fidelity DNA Polymerase was used to PCR amplify the library, which was then submitted to a post-PCR cleanup using AMPure XP beads.
characteristics.characteristic: description
characteristics.text: adult
characteristics.characteristic: developmental stage
characteristics.text: pancreatic ductal adenocarcinoma
characteristics.characteristic: disease
characteristics.text: GPDX 13
characteristics.characteristic: individual
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: pancreas
characteristics.characteristic: organism part
characteristics.text: Homo sapiens
characteristics.characteristic: scientific name
characteristics.text: GPDX 13 Vehicle
characteristics.characteristic: title
characteristics.text: subcutaneous injection in NMRInu/nu mice until neoplasm formation
characteristics.characteristic: xenograft